Coagulopathy associated with COVID-19 infection and risk of thromboembolism – do we know their relationship and subsequent solution?
Authors:
Katarína Bielaková; Ondřej Ludka
Authors place of work:
Klinika interní, geriatrie a praktického lékařství LF MU a FN Brno
Published in the journal:
Geriatrie a Gerontologie 2022, 11, č. 2: 84-89
Category:
Review Article
Summary
At the end of 2019, a new coronavirus SARS-CoV-2 was identified, which caused a global pandemic. This acute infectious disease is associated with coagulopathy, which leads to a hypercoagulable state in patients. Coagulopathy in this disease is complex in feature and involves a number of different factors. Patients result in a high risk of venous as well as arterial thrombosis. This finding leads to the inclusion of measures in hospitalized and outpatient patients to reduce the proportion of thromboembolism in COVID-19 infection.
Keywords:
Cytokines – Prophylaxis – coagulopathy – treatment – COVID-19 – thrombosis – risk factors
Zdroje
1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Dostupné z: https:// coronavirus.jhu.edu/map.html
2. Ali MAM, Spinler SA. Covid-19 and thrombosis: From bench to bedside. Trends in Cardiovascular Medicine 2021; 31: 143–160.
3. Zhang R, Ni L, Di X, et al. Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients. J Vasc Surg Venous Lymphat Disord 2021; 9(2): 289–298.
4. Li JY, Wang HF, Yin P, et al. Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: a multicenter retrospective study. J Thromb Haemost 2021; 19(4): 1038–1048.
5. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421–1424.
6. Klok FA, Krup M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148–150.
7. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18(8): 1995–2002.
8. Ahujaa N, Bhindera J, Nguyena J, et al. Venous thromboembolism in patients with COVID-19 infection: risk factors, prevention, and management. Semin Vasc Surg 2021; 34(3): 101–116.
9. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128.
10. Merad M, Martin JC. Author correction: pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20(7): 448.
11. Argañaraz GA, Palmeira JF, Argañaraz ER. Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19. Cell Commun Signal 2020; 18(1): 190.
12. Vojáček JF. Trombotické komplikace Covid-19. Krátký přehled současných názorů. Interv Akut Kardiol 2021; 20(2): 98–101.
13. Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020; 99: 47–56.
14. Bílková S, Hirmerová J. Koagulopatie asociovaná s onemocněním COVID-19. Vnitř Lék 2020; 66(7): 402–408.
15. Dakay K, Cooper J, Bloomfield J, et al. Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature. J Stroke Cerebrovasc Dis 2021; 30(1): 105434.
16. Tu TM, Goh C, Tan YK, et al. Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review. J Stroke Cerebrovasc Dis 2020; 29(12): 105379.
17. Singh B, Kaur P, Maroules. Splanchnic vein thrombosis in COVID- 19: a review of literature. Dig Liver Dis 2020; 52(12): 1407– 1409.
18. Choi JJ, Wehmeyer GT, Li HA, et al. D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. Thromb Res 2020; 196: 318–321.
19. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136: 489– 500.
20. Dujardin RWG, Hilderink BN, Haksteen WE, et al. Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. Thromb Res 2020; 196: 308–312.
21. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID- 19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020; 50(1):72–81.
22. Daughety MM. COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res 2020; 196: 483–485.
23. Donesu PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy 2020; 40(11): 1130– 1151
24. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsie. Mod Pathol 2020; 33(6): 1007–1014.
25. Zhou X, Cheby Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res 2021; 201: 23–29.
26. Fraisse M, Logre E, Pajot O, et al. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care 2020; 24(1): 275.
27. Jiménez D, Garcia-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2021; 159(3): 1182–1196.
28. Kwok B, Brosnahan SB, Amoroso NE, et al. Pulmonary embolism response team activation during the COVID-19 pandemic in a New York City academic hospital: a retrospective cohort analysis. J Thromb Thrombolysis 2021; 51(2): 330– 338.
29. Štefan M, Chrdle A, Husa P, et al. Covid-19 diagnostika a léčba. Doporučený postup Společnosti infekčního lékařství ČLS JEP. Klinická mikrobiologie a infekční lékařství. 2021; 27(2): 61– 87.
Štítky
Geriatrics General practitioner for adults Orthopaedic prostheticsČlánok vyšiel v časopise
Geriatrics and Gerontology
2022 Číslo 2
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Non-melanoma skin tumors – basalioma, spinalioma. Overview of the disease and treatment
- Midline catheters for geriatric patients in Postacute Care Facility
- Drug interactions in gerontopsychiatry – the choice of antipsychotics and antidepressants for geriatric patients
- Urinary incontinence in old age